ESPR 250117 2.00C (ESPR250117C2000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ESPR250117C2000

Watchlist

0.15
0.000.00%

15min DelayClose Jan 17 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Express News | Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersFeb 13 16:30 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswireFeb 13 16:30 ET
JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Cuts Target Price to $4
Moomoo NewsFeb 11 00:32 ET · Ratings
Express News | JMP Securities Reiterates Market Outperform on Esperion Therapeutics, Maintains $7 Price Target
BenzingaJan 23 09:44 ET
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $2.05 to $16
Moomoo NewsJan 23 08:00 ET · Ratings
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Moomoo NewsJan 10 06:31 ET · Ratings

Comments

alson102446937

Feb 13 20:27

$Esperion Therapeutics (ESPR.US)$ As of February 13, 2025, the stock price of ESPR was $1.87, slightly down 0.53% from the previous trading day. Despite the negative fund flow, the stock price did not decline significantly, which may indicate that the market has a relatively positive outlook on the company.

Narga101

Feb 13 07:20

got my eye on this

$Esperion Therapeutics (ESPR.US)$

10xStockPicks

Feb 11 22:57

Cafe Pharma Highlights This Biotech As A Definite Acquisition Candidate. This Is Extremely Undervalued And Will Return Investors 5x to 10x.

Link for article here Real Rumors Daiichi Sankyo Europe Has Intentions To Acquire Esperion Therapeutics $Esperion Therapeutics (ESPR.US)$ . .
Daiichi Sankyo Europe (DSE) Poised to Acquire Esperion Therapeutics Amid Leaked Insider Information
Recent rumors circulating on social media, supported by credible leaks from individuals connected to both DSE and E...

alson102446937

Feb 9 22:09

$Esperion Therapeutics (ESPR.US)$ JMP Securities analyst Roy Buchanan reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Market Outperform and maintains $7 price target. News: Benzinga. Jan 23 22:44
JMP 证券分析师 Roy Buchanan 重申了对 Esperion Therapeutics (NASDAQ:ESPR) 股票的市场表现优于大盘评级，并维持 7 美元的目标股价。

70659822

Feb 5 00:38

$Esperion Therapeutics (ESPR.US)$
i observed for years that 6 out of 10 persons are overweight or obese. For ESPR with a good med. that can help people to defend the obesity epidemic, how can its stock price keep falling?!